Publications by authors named "Thomas Staab"

Claim this Profile
"
"Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
Thomas R Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J-Matthias Graf von der Schulenburg

Health Econ Rev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
Georg Isbary, Thomas R Staab, Volker E Amelung, Charalabos-Markos Dintsios, Christof Iking-Konert

Value Health· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
Jörg Ruof, Thomas Staab, Charalabos-Markos Dintsios, Jakob Schröter, Friedrich Wilhelm Schwartz

Health Econ Rev· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
Thomas Staab, Georg Isbary, Volker E Amelung, Jörg Ruof

BMC Health Serv Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
Jörg Ruof, Dietrich Knoerzer, Anja-Alexandra Dünne, Charalabos-Markos Dintsios, Thomas Staab

Health Policy· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis